Nonviral Vectors for Gene Therapy, Volume 89

• Advances in Genetics, Volume 89
• Dedication
• Chapter One. Physical Methods for Gene Transfer
  • 1. Introduction
  • 2. Most Commonly Used Physical Methods
  • 3. Future Perspectives
• Chapter Two. Nonviral Gene Delivery Systems by the Combination of Bubble Liposomes and Ultrasound
  • 1. Introduction
  • 2. Microbubbles and Ultrasound
  • 3. Bubble Liposomes
  • 4. In vitro pDNA Delivery with BLs
  • 5. In vivo pDNA Delivery with BLs
  • 6. In vitro/In vivo Small Interfering RNA Delivery with BLs
  • 7. siRNA-Loaded BLs
  • 8. MicroRNA-Loaded BLs
  • 9. Endosomal Escape Enhanced by BLs
  • 10. Conclusions
• Chapter Three. Electroporation-Mediated Gene Delivery
  • 1. Introduction
  • 2. Theory of Membrane Electroporation
  • 3. Mechanism(s) of Electroporation-Mediated Gene Delivery
  • 4. Pulse Parameters
  • 5. Electrodes
  • 6. Tissues that can be Directly Injected: Liver and Skeletal Muscle
  • 7. Electroporation of Skeletal Muscle: DNA Vaccines and Use as Bioreactors
  • 8. Electroporation of Skin: Vaccination, Wound Healing, and Cancer
  • 9. Electroporation of the Cardiovascular System
  • 10. Gene Delivery into the Lung Using Electroporation
  • 11. Conclusions
• Chapter Four. Hydrodynamic Delivery
  • 1. Fundamentals of Hydrodynamic Delivery
  • 2. Applications of Hydrodynamic Gene Delivery
  • 3. Hydrodynamic Delivery in Large Animals—Toward Clinic Application
  • 4. Future Prospective
• Chapter Five. Sustained Expression from DNA Vectors
  • 1. Introduction
  • 2. Immune Responses
  • 3. Preventing Epigenetic Silencing
  • 4. Position Effect
  • 5. Persistent Nonintegrating Episomal DNA Vectors
  • 6. Episomal DNA Vectors Based on Replication-Deficient Viruses
  • 7. Episomal DNA Vectors Based on Chromosomal Elements
  • 8. Mammalian Artificial Chromosomes
  • 9. Episomally Maintained pDNA Vectors
  • 10. Scaffold/Matrix Attachment Regions
  • 11. Insulator Function
  • 12. Transcription Augmentation
  • 13. Mitotic Stability
  • 14. Persistent Expression Mediated by S/MAR DNA Vectors
  • 15. Alternative Elements to Modulate Transcription Levels of DNA Vectors
  • 16. Optimization of Episomal Vectors for Gene Therapy
  • 17. Promoters and Enhancers
  • 18. The CMV Promoter
  • 19. The UbC Promoter
  • 20. The AAT Promoter
  • 21. Enhancers
  • 22. Posttranscriptional Regulation
  • 23. Effect of CpG Depletion
  • 24. Studies Demonstrating Passive Episomal State of Minicircles In vivo
  • 25. Conclusions
• Chapter Six. Noncoding Oligonucleotides: The Belle of the Ball in Gene Therapy
  • 1. Introduction
  • 2. Noncoding Oligonucleotides-Based Therapeutics in Gene Therapy
  • 3. Challenges for Successful Gene Therapy Using Noncoding Oligonucleotides
  • Conflict of Interest Statement
• Chapter Seven. Self-Amplifying mRNA Vaccines
  • 1. Introduction
  • 2. History of Nucleic Acid Vaccines
  • 3. Introduction to mRNA Vaccines
  • 4. Self-Amplifying mRNA
  • 5. Delivery of Self-Amplifying mRNA Vaccines
  • 6. Production and Purification of Self-Amplifying mRNA
  • 7. Stability of mRNA
  • 8. Future Prospects for Nonviral Delivery of Self-Amplifying mRNA Vaccines
• Chapter Eight. Gene Electrotransfer Clinical Trials
  • 1. Introduction
  • 2. GET in Clinical Trials
  • 3. Summary and Conclusions
• Index

The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. Advances in Genetics continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines.

• Includes methods for testing with ethical, legal, and social implications
• Critically analyzes future directions
• Written and edited by recognized leaders in the field

Molecular geneticists, clinical geneticists, neurologists, neuroscientists, molecular biologists, and biochemists.